SICGEN
Private Company
Funding information not available
Overview
SICGEN is a Lisbon-based biotech firm established in 2001, operating as a specialized provider of custom and catalog polyclonal antibodies for the research market. The company functions on a hybrid product and service model, developing antibodies in-house and distributing them globally, with a focus on environmental sustainability in its shipping practices. It has successfully served major international academic and industrial research customers and has received co-financing from the European Union's Horizon 2020 program. SICGEN appears to be a stable, revenue-generating private company focused on the research tools segment of the biotechnology industry.
Technology Platform
Traditional polyclonal antibody production in goats, utilizing modern immunogen design and purification techniques. Focus on generating high-specificity antibodies for research applications.
Opportunities
Risk Factors
Competitive Landscape
SICGEN competes in the fragmented research antibodies market against large multinationals (e.g., Thermo Fisher, Abcam, Merck) and numerous small-to-mid-size specialists. Its differentiation is based on competitive pricing, quality in polyclonal production, and personalized custom service, targeting cost-conscious academic and industrial labs.